This is the story of the most profitable private equity buyout of all time and it’s French 🇫🇷 Company : Polyplus-Transfection Sector : Healthcare 💊 Sponsor : Archimed Here is a thread on how Archimed achieved a 300x MOIC on its initial investment 🧵👇

Valuations for European mid-market deals continue to decline, reaching levels not seen in years. 1. Argos Index fell to 8.7x EV/EBITDA, the lowest level since 2017 2. Both Private Equity and strategics are paying down (resp. 9x and 7.7x) 3. Only 7% of deals are now closed above

APOL1 Genetic Testing at No Cost to Patients! Are you incorporating APOL1 genetic testing into your workflow? Discover No-Cost APOL1 Genotyping Program for eligible patients sponsored by Vertex Pharmaceuticals. Learn more today!

I am looking for someone who is an LP in Blackstone Strategic Partners IX, Please DM

Secondary Opportunity 💡 I know a piece of a European infrastructures fund that is currently for sale in the secondary market.  We are already investors and have a good sense of the GP, the portcos quality, and expected exits. Two exits are incoming in the next six months. The

Secondary Opportunity 💡 I know a piece of a European infrastructures fund that is currently for sale in the secondary market.  We are already investors and have a good sense of the GP, the portcos quality, and expected exits. Two exits are incoming in the next six months. The

Interesting read on AI in PE from Pitti 👇 AI in Private Equity: Deconstructing the Pitch

A few interesting data points from Stepstone suggesting that Private equity Buyout valuations are not entirely off. 1. Despite lower exit activity, there is still an uplift to NAV at exit: 5 quarters prior uplift stands at 16% vs. 27% historical average. 2. There is still a

35% of Private Equity exits were achieved through a continuation fund in H1 2025, according to Stepstone

Fund finance has become an asset in itself. Here is a chart summarizing all types of possible structures per Aberdeen

Anyone involved in financing secondary deals? Would need a small NAV loan (approx $10million) (25-35% LTV) on a diversified collateral (100% buyout).

Anyone involved in financing secondary deals? Would need a small NAV loan (approx $10million) (25-35% LTV) on a diversified collateral (100% buyout).

That’s 100% true. We sold a direct lending fund earlier this year at 99, 5% of NAV. The problem with private debt secondaries is that the remaining duration is very short, and you don’t have any upside, which means your ultimate multiple is made of 1 or 2 years of interest

📈H1 2025 Portfolio Performances 💵Private Equity: -0, 8% 🚝Infrastructures : +3.5% 🏢Real Estate: +0, 2% (o/w 3% cash yield / -2, 8% NAV decrease) 💰Private Credit: +2, 25% ( o/w 3.25% Cash yield, -1% NAV decrease) Not a good first half of the year.

I attended a private market conference last week, and I can tell you that the frontier between public and private markets is becoming increasingly blurred. For instance, Blackstone is aggressively pitching its “Private Investment Grade” solution. They originate IG private loans

🚨Opportunity - Direct co-investment opportunity (no fee, no carried interest) in a company we invested in 3 years ago. Key characteristics : Maritime / Shipping industry 🚢 Modern and eco fleet of Gas Carriers and Offshore Wind Service vessels long-term chartered to IG blue

🚨Opportunity - Direct co-investment opportunity (no fee, no carried interest) in a company we invested in 3 years ago. Key characteristics : Maritime / Shipping industry 🚢 Modern and eco fleet of Gas Carriers and Offshore Wind Service vessels long-term chartered to IG blue

The current state of the secondary market is summed up by a broker in his Q3 market update 👉”For years, venerable institutional secondary managers have enjoyed rich returns, underpinned by disciplined underwriting. Those times are over. Performance has been sacrificed on the

The current state of the secondary market is summed up by a broker in his Q3 market update 👉”For years, venerable institutional secondary managers have enjoyed rich returns, underpinned by disciplined underwriting. Those times are over. Performance has been sacrificed on the

I’ve often said that evergreen funds are distorting secondary pricing and overpaying, especially for LP-led deals. But here is the evidence from Evercore. Evergreens are overbidding by up to 25% point above traditional closed-end secondary players. That is going to end in very

Thanks god, the market is healing!

In the last 12/18 months, I’ve also noticed a clear trend regarding GP-led. It is the penetration of continuation vehicles in the lower end of the market. Once reserved for UMM/ large cap companies, they’re now adopted by MM or LMM players.